ASX Health Stocks: Anteris implants its novel aortic valve DurAVR into 8 more patients
Health & Biotech
Health & Biotech
Anteris (ASX:AVR) reported that eight more patients were successfully treated last week, as part of its ongoing first-in-human DurAVR THV study conducted in the country of Georgia.
Anteris’ chief medical officer, Dr Chris Meduri, has overseen the study, including the initial five aortic stenosis patients implanted with DurAVR THV last November at Georgia’s Tbilisi Heart and Vascular Clinic.
Australian physician Dr Karl Poon was also in attendance, and became the first Australian doctor to implant a patient with the DurAVR THV.
The DurAVR is said to be the world’s first and only 3D single piece aortic valve.
The unique design of DurAVR, coupled with Anteris’ ADAPT technology, provides the potential to deliver a more durable heart valve that delivers better haemodynamics performance.
It does this by creating a wider valve opening to allow better blood flow. It’s also easy to implant, requiring only a few stitches.
Data from the latest cohort will be reviewed at the 30-day follow-up, which is the key inflection point for indicating ongoing valve performance.
“We are thrilled with the ongoing progress and the veracity of the results so far,” said Anteris CEO Wayne Paterson.
“The company continues to progress its clinical program, and I look forward to updating the market in the near future,” he added.
Emyria (ASX:EMD) announced a substantial expansion of its exclusive partnership with the University of Western Australia (UWA) to build and screen a proprietary MDMA analogue library.
Under the expanded agreement, Emyria will provide an additional $450,000 to UWA and Dr Matt Piggott’s research group over the next 12 months.
This funding follows on from the initial agreement entered into with UWA in August last year.
Upon completion, Emyria will hold an exclusive option to license and commercialise the most promising compounds (and their associated patent families).
“Emyria’s clinical development expertise, funding and international networks have taken our MDMA analogue research to the next level,” said Dr Piggott, who developed the initial library of over 100 unique compounds.
Emyria’s CEO, Dr Michael Winlo, said that initial screening results have been very positive.
“In a short timeframe, we have identified several promising lead drug candidates which we are now advancing to preclinical screening,” Winlo said.
“This MDMA partnership is a core part of Emyria’s growing drug development pipeline, and complements our ultra-pure cannabinoid program led by EMD-RX5,” he added.